Diagnostics company Novacyt UK has agreed to purchase UK-based genomic medicine company Yourgene Health in a £16.7m ($21.3m) deal.

Researchers have used laboratory-on-a-chip technology to create a low cost, sensitive tuberculosis (TB) test that could improve disease detection in high-endemic, under-resourced areas.

The US Food and Drug Administration (FDA) has granted approval for Lumos Diagnostics’ FebriDx rapid point-of-care (POC) test.

PamGene International said Tuesday that the European Innovation Council's Accelerator program will provide €7.5 million ($8.2 million) in funding to develop and market the firm's prognostic test for immunotherapy response in metastatic cancer treatment.

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

Paige is enhancing its suite of AI-enabled solutions designed to support pathologists in the diagnosis of breast cancer while decreasing subjectivity and the tedium of manual analysis.

On March 30 2023, Kalorama Information indicates that the global IVD market is now over $124 billion, with operations in more than 20 key healthcare and medical areas, such as infectious disease immunoassays, POC, molecular microbiology, clinical chemistry, etc.

Becton, Dickinson and Company (BD) has globally introduced the new automated instrument, the BD FACSDuet Premium Sample Preparation System, for cellular diagnostic applications.

Asep Medical has entered a definitive agreement with Seaspring for sepsis diagnosis technology Sepset.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.